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2-4 key messages: detailing concisely the main points of the paper 
x Policy makers in low- and middle-income countries on the path to universal health 
coverage face hard choices about which services to prioritise and how to scale up 
delivery 
x These choices can involve equity trade-offs between improving total health and reducing 
social inequalities in health 
x We show how such equity trade-offs can be quantified, and how policy makers can use 
this information to make transparent decisions, using the example of rotavirus 
vaccination in Ethiopia  
x We do this using a new method called distributional cost-effectiveness analysis, which 
we adapt for use in low- and middle-income country settings 
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Abstract 
Reducing health inequality is a major policy concern for low- and middle-income countries 
(LMICs) on the path to universal health coverage. However, health inequality impacts are 
rarely quantified in cost-effectiveness analyses of health programmes. Distributional cost-
effectiveness analysis (DCEA) is a method developed to analyse the expected social 
distributions of costs and health benefits, and the potential trade-offs that may exist between 
maximising total health and reducing health inequality. This is the first paper to show how 
DCEA can be applied in LMICs. Using the introduction of rotavirus vaccination in Ethiopia as 
an illustrative example, we analyse a hypothetical re-designed vaccination programme, 
which invests additional resources into vaccine delivery in rural areas, and compare this with 
the standard programme currently implemented in Ethiopia. We show that the re-designed 
programme has an incremental cost-effectiveness ratio of US$69 per health adjusted life 
year (HALY) compared with the standard programme.  This is potentially cost-ineffective 
when compared with current estimates of health opportunity cost in Ethiopia.  However, rural 
populations are typically less wealthy than urban populations and experience poorer lifetime 
health. Prioritising such populations can thus be seen as being equitable. We analyse the 
trade-off between cost-effectiveness and equity using the Atkinson inequality aversion 
parameter, , representing WKHGHFLVLRQPDNHU¶VVWUHQJWKRIFRQFHUQIRUUHGXFLQJKHDOWK
inequality. We find that the more equitable programme would be considered worthwhile by a 
decision maker whose inequality concern is greater than =5.66, which at current levels of 
health inequality in Ethiopia implies that health gains are weighted at least 3.86 times more 
highly in the poorest compared with the richest wealth quintile group. We explore the 
sensitivity of this conclusion to a range of assumptions and cost-per-HALY threshold values, 
to illustrate how DCEA can inform the thinking of decision makers and stakeholders about 
health equity trade-offs. 
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Introduction 
Tackling inequalities is a key feature of global health policy agendas and underpins the 
sustainable development goals and associated universal health coverage movement 
(Marmot et al., 2012, United Nations, 2015, Ottersen et al., 2014). However, methods of 
cost-effectiveness analysis (CEA) used in mainstream healthcare decision making focus on 
the objective of maximising population health rather than reducing unfair health inequalities 
(Sassi et al., 2001, Weatherly et al., 2009, Johri and Norheim, 2012). Recent methodological 
DGYDQFHVKDYHHQKDQFHG&($PHWKRGVWRHQDEOHWKHPWRJREH\RQGWKHP\WKLFDOµDYHUDJH¶
citizen and consider the social distribution of costs and benefits (Cookson et al., 2017). 
Notable amongst these methodological GHYHORSPHQWV DUH ³H[WHQGHG´ FRVW-effectiveness 
analysis (ECEA), which provides breakdowns of costs and benefits by social groups (e.g. 
income, area of residence, sex) DQG ³GLVWULEXWLRQDO´ FRVW-effectiveness analysis (DCEA) 
which, in addition, provides summary measures of health inequality impact and analyses 
potential trade-offs between increasing total health and reducing health inequality (Verguet 
et al., 2015a, Asaria et al., 2015).  
ECEA expands traditional CEA to examine the effects of an intervention on financial risk 
protection (safeguarding against financial hardship associated with paying for health 
services) as well as on health outcomes (Verguet et al., 2015a, Verguet et al., 2016). It 
breaks down the costs, health benefits and financial risk protection benefits by social groups 
(usually income groups). However, ECEA does not account for health opportunity costs of 
displaced expenditure within the health sector budget neither does it provide any guidance 
on how to resolve equity-efficiency trade-offs (Verguet et al., 2015b, Levin et al., 2015, 
Pecenka et al., 2015). 
DCEA provides an explicit framework for analysing the social distribution of health benefits 
and opportunity costs and the equity trade-offs that may arise between improving total health 
and reducing health inequality (Asaria et al., 2015). It examines the distribution of outcomes 
similarly to ECEA but goes further by enabling transparent analysis of health opportunity 
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costs, summary measures of health inequality impact, and equity trade-offs, with the aim of 
providing decision makers with a clearer understanding of the health inequality impacts and 
trade-offs and the implications of alternative social value judgements about equity (Asaria et 
al., 2016). Social factors such as income, education, socioeconomic status can impact on 
the health of individuals over their lifetime and cause inequalities in lifetime health between 
social groups. DCEA facilitates the inclusion of impacts on overall inequality in lifetime 
health, rather than on inequality in health gains directly from the intervention, by accounting 
for the effects of an intervention on the distribution of lifetime health (Asaria et al., 2014). 
However, DCEA does not account for non-health benefits such as financial risk protection. 
To date, DCEA has primarily been applied to research in England (Asaria et al., 2015), while 
ECEA has been used extensively to explore the distribution of outcomes of health policies in 
low- and middle-income countries (LMICs) (Verguet S and Jamison, forthcoming); though 
some previous research in LMIC settings has used some components of DCEA (Johansson 
and Norheim, 2011, Ngalesoni et al., 2016). In this paper we apply DCEA to an illustrative 
example of scaling up rotavirus vaccination in Ethiopia and show how the different 
components of DCEA can be applied in LMIC settings. In doing so we aim to demonstrate 
how to overcome the various challenges of applying these data intensive methods in 
relatively data sparse contexts and showcase some of the insights that such an analysis can 
provide to health policy makers in such contexts. 
 
Methods 
Publicly Funded Rotavirus Vaccination 
Rotavirus is responsible for around a third of global diarrhoea-related deaths, the majority of 
which occur in LMICs (Liu et al., 2012, Tate et al., 2012). Before vaccination was introduced 
in 2013, Ethiopia had the fifth highest number of rotavirus related deaths (28,218 per year) 
worldwide. The vaccine has been found to be effective in many countries around the world, 
reducing severe rotavirus disease by more than 60% in the first year of life (Madhi et al., 
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2010, Armah et al., 2010). The most recent estimate of vaccine coverage from Ethiopia DHS 
2016 is 56%, however, coverage varies across groups (Central Statistical Agency (CSA) 
[Ethiopia] and ICF, 2016). Since its introduction, coverage has been lowest amongst the 
poor in Ethiopia (Central Statistcal Agency [Ethiopia], 2014). As more of the population in 
poorer wealth quintile groups live in rural areas, by targeting these areas it may be possible 
to increase coverage amongst the poor (Central Statistcal Agency [Ethiopia] and Living 
Standards Measurement Study (LSMS), 2017). However, there are higher delivery costs in 
rural areas due to a range of logistical challenges.  
 
Comparing DCEA and ECEA 
To illustrate the value of DCEA, we built on a previous ECEA conducted before the 
introduction of the rotavirus vaccine in Ethiopia (Verguet et al., 2013a). We began by 
evaluating the existing rotavirus vaccinatioQSURJUDPPHIURPWRWKH³VWDQGDUG´
vaccination programme), compared to the prior situation of no vaccination in 2012, using the 
same assumptions as the original ECEA model but updating the coverage assumptions to 
the levels actually achieved in different groups by 2016. We then evaluate a hypothetical 
alternative re-GHVLJQHG YDFFLQDWLRQ SURJUDPPH IURP  WR  WKH ³SUR-SRRU´
vaccination programme) that would have made proportionally more effort to deliver 
vaccination in rural areas. We incorporated health opportunity costs into our analyses to 
FRPSXWH³QHW´KHDOWKJDLQVE\VRFLDOJURXS:HSODFHGWKHVHKHDOWKJDLQV LQWRWKHEURDGHU
context of differences in lifetime health, and finally examined the trade-offs between cost-
effectiveness and health equity. We focused on equity in terms of the distribution of health 
between population wealth quintiles; however, we note this is only one possible dimension 
by which equity may be considered. It is possible to conduct similar analysis by other 
dimensions of interest such as, gender, age, ethnicity, geography, if the relevant data is 
available. 
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Parameters 
Parameters used to evaluate each vaccination programme are presented in Table 1. 
Rotavirus death rate, relative risk of rotavirus mortality and vaccine effectiveness were taken 
from the original ECEA study (Verguet et al., 2013a). All other parameters were updated to 
use more recent estimates or to represent the pro-poor hypothetical programme. Differential 
health risks were reflected in the fact that poorer children were more likely to contract 
rotavirus and more likely to die if they did.  The vaccine was assumed to have equal 
effectiveness in all groups, instantaneous scale-up was assumed, with the primary health 
outcome being rotavirus diarrhoea deaths averted (Verguet et al., 2013a).  
Costs were calculated as the vaccine cost plus the cost of delivering the vaccine and are 
presented in US dollars. These were applied to the population receiving the vaccine from an 
approximate annual birth cohort of 2,800,000, taking account of differential fertility rates by 
wealth quintile group  (Central Statistical Agency [Ethiopia], 2014). The benefits of the 
vaccine were calculated as deaths averted in children under 5 years old, which were 
converted to healthy life years (HALYs) (essentially the same as quality adjusted life years 
(QALYs), see Appendix 1 for some of the methodological nuances). 
Consideration was given to how health opportunity costs ± i.e. health forgone elsewhere in 
the system as a result of introducing the vaccine programme ± were distributed among the 
population. The assumed distribution of the opportunity costs of reduced public healthcare 
expenditure is shown in Table 17KLVLQYHUWHGµ8¶VKDSHwas based on the assumption that 
the poorest group had the lowest opportunity costs, as government health expenditure does 
not often reach them, while the richest group had similarly low opportunity costs as they 
were most likely to opt out of government funded healthcare preferring instead to purchase 
healthcare from private providers. Alternative assumptions were considered and are 
presented in Appendix 3 along with their effect on results. 
The cost-effectiveness threshold (CET) was used to assess whether an intervention 
improved total health, after allowing for other forgone investments. There are a range of 
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possible values that could be used to represent the CET for Ethiopia. For the base case 
analysis we made the assumption that the CET for Ethiopia was $50 per HALY. This CET 
was chosen for two reasons: first, it falls within the range recommended ($10-$255) in the 
analysis by Woods et al. (2016) and therefore represents a plausible empirical estimate of 
health opportunity cost in Ethiopia; second, it was chosen as it enabled us to clearly illustrate 
the trade-off between equity and efficiency in this example. It is notable, however, that the 
WHO recommended threshold range of 1-3 time GDP per capita is substantially higher 
($619-$1,875). Consequently, we assess the impact of alternative CETs within the range 
$10-$1,857 in sensitivity analyses. 
 
The Baseline Distribution of Lifetime Health 
The baseline distribution of lifetime health describes how the overall burden of mortality and 
morbidity is distributed among different social groups within the general population. This 
allows consideration of the effects of an intervention on inequality in lifetime health, by 
comparing the distribution of lifetime health at baseline to that which would result following a 
new health intervention. Mortality and morbidity may vary by gender, age, ethnicity, wealth 
and many other factors. The factors that are used to estimate the distribution of lifetime 
health in a population will depend on the data available and the dimensions deemed relevant 
for the distributional evaluation undertaken. The baseline health distribution must be 
estimated for the general population, not just for those receiving the intervention.  This is 
because policy concern for inequality encompasses inequality within the entire general 
population, and the opportunity costs of displaced resources will likely fall on members of the 
wider population including those who do not directly benefit from the intervention being 
evaluated (Asaria et al., 2016). 
In the absence of reliable census and vital statistics data in Ethiopia (as is also the case in 
many other low-income countries), we used indirect estimates of mortality differences by 
social strata drawing on WHO data on healthy life expectancy (HALE) and Demographic and 
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Health Survey (DHS) data on morbidity and mortality by household asset wealth group in 
order to estimate the distribution of lifetime health. Population average HALE values, 
measured in HALYs, were taken from the WHO Life Expectancy database (World Health 
Organisation, 2015, Salomon et al., 2012). These average HALE values were weighted by 
mortality based on previously modelled life expectancy by socioeconomic group, drawing on 
DHS data on child mortality by household asset group (Tranvag et al., 2013). Finally, the 
values were weighted by morbidity based on available prevalence data by socioeconomic 
group (GBD, 2010, IHME, 2015). The groups were then ordered from least to most healthy 
and population weighted to create the baseline distribution of HALE at birth. Detailed 
descriptions of these calculations are provided in Appendix 1. 
 
Equity Impact Analysis 
Using the same modelling assumptions as Verguet et al. (2013a), costs (see Table 1), 
calculated as the vaccine cost plus the delivery cost, and health effects, calculated as deaths 
averted due to the vaccine, were estimated for each wealth quintile group (see Appendix 2). 
Costs were assigned based on the proportion of each quintile group living in urban/rural 
areas (Central Statistical Agency [Ethiopia], 2014). Opportunity costs and health benefits 
were calculated in terms of HALYs.  Deaths averted were multiplied by the HALE values for 
the corresponding quintile group from the baseline health distribution to estimate total 
HALYs gained in each group, from which per capita HALY gain was calculated. Assuming a 
constant population over time, the additional HALYs gained were added to the baseline 
HALE to give an estimation of the HALE distribution after the introduction of the vaccination 
programme. Using the net benefit approach, total costs of the vaccine programme were 
divided by an assumed base-case CET value of $50 per HALY to convert costs into health 
opportunity costs (alternative thresholds were assessed in sensitivity analyses). Net health 
benefits ( ) were thus calculated for each wealth quintile group (J) as: 
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 (1) 
 
Equity Trade-off Analysis 
To evaluate any trade-offs between improving total health and reducing inequality in health, 
we used an Atkinson social welfare function with relative inequality aversion parameter, , to 
UHSUHVHQW WKH GHFLVLRQ PDNHU¶V VWUHQJWK RI FRQFHUQ IRU UHGXFLQJ KHDOWK LQHTXDOLW\. This 
SDUDPHWHUGHVFULEHVWKHGHFLVLRQPDNHU¶VZLOOLQJQHVVWRPDNHWUDGH-offs between improving 
total health and reducing health inequality (Asaria et al., 2015). We focused on this single 
index of inequality aversion in order to keep the paper simple and concise. However, 
different social welfare functions can be used in DCEA to represent different kinds of 
inequality concern ± for example, absolute health inequality ± as illustrated by Asaria and 
colleagues (2015). The nature of the inequality concern should drive the selection of 
inequality indices and it may be useful to employ several such measures in sensitivity 
analyses. We used DCEA to compare the two alternative vaccination strategies in equity-
cost-HIIHFWLYHQHVVVSDFHXVLQJWKH³KHDOWKHTXLW\LPSDFWSODQH´ in which the effect on health 
was quantified as in standard CEA, and the health inequality impact is quantified by the 
UHGXFWLRQLQWKH$WNLQVRQLQGH[RIIHUHGE\WKH³pro-poor´YDFFLQDWLRQSURJUDPPHFRPSDUHG
ZLWKWKH³VWDQGDUG´SURJUDPPH 
To use the Atkinson index one must choose a value for the inequality aversion parameter. A 
value for the inequality aversion parameter (İ) equal to 0 indicates there is no aversion to 
inequality and a Utilitarian perspective is represented. As the value of İ increases, higher 
priority is given to transfers lower in the distribution (the worse off). An empirical study in 
England has estimated an Atkinson relative health inequality aversion parameter as 10.95 
(Robson et al., 2016). This was used as a tentative reference point for the analysis. 
Extensive sensitivity analysis was conducted to explore the impact of using alternative 
values of the inequality aversion parameter.  
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The equity-efficiency trade-off can be depicted by calculating the equally distributed 
equivalent (EDE) level of health that, if obtained by every individual, would enable a society 
to reach the same level of overall health as the current modelled distribution of health 
(Asaria et al., 2015). This allows alternative interventions or strategies to be compared for 
any given level of inequality aversion. 7KHGLIIHUHQFHEHWZHHQDSRSXODWLRQ¶VPHDQOHYHORI
health and the EDE for health indicates the average amount of health per person that society 
(or the decision maker) is willing to sacrifice to achieve an equal distribution of health for a 
given level of inequality aversion, conditional on the current inequality in the population 
health distribution (Asaria et al., 2015). We therefore plotted EDE for each strategy at a 
range of levels of inequality aversion İ WR VKRZ ZKLFK RSWLRQ ZRXOG EH SUHIHUUHG WDNLQJ
account of the trade-off between overall health and health equity. We conducted equity 
trade-off analysis for the base case at a CET value of $50. In addition a range of alternative 
CET values were also used to explore the equity-efficiency trade-off in sensitivity analyses. 
 
 
Results 
The Baseline Distribution of Lifetime Health 
Figure 1 shows the estimated baseline distribution of HALE at birth in each wealth quintile 
group of the Ethiopian population compared with the life expectancy in each group. The 
HALE values are lower than the life expectancy values because of the adjustment for 
morbidity. This adjustment is greater in the lower wealth quintile groups due to higher levels 
of morbidity in these groups. 
 
Equity Impact Analysis 
Step by step calculation of the distribution of NHB resulting from the equity impact analysis is 
given in Table 2 and the resulting distribution is shown in Figure 2, for each vaccination 
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programme compared to no vaccination. This shows that, compared with the standard 
programme, the pro-poor programme provides greater gains to the lowest wealth quintile 
groups at the expense of the higher wealth quintile groups. 
 
Equity Trade-off Analysis 
The cost-effectiveness plane, Panel A of Figure 3, shows the pro-poor vaccine compared to 
the standard vaccine as would be presented in standard CEA. The pro-poor vaccine is not 
cost-effective at a threshold of $50 per HALY as compared to the standard vaccination 
programme. +RZHYHUXVLQJWKH³KHDOWKHTXLW\LPSDFWSODQH´VKRZQLQ3DQHO%RI)LJXUH
we compare the two strategies in equity-cost-effectiveness space. The pro-poor vaccine falls 
in the south-HDVW³ORVH-ZLQ´TXDGUDQW&(7=$50), demonstrating that relative to the standard 
vaccination programme it has a positive impact on health equity despite its negative impact 
on total health. Thus, a trade-off occurs between improving total health and reducing 
socioeconomic inequality in health. Figure 3 also presents the equity trade-off analysis at the 
four CET values selected for the sensitivity analyses to show how the choice of threshold 
impacts on the results. 
The difference in the EDE health of the two vaccination strategies at a range of levels of 
relative inequality aversion, İDUHGHSLFWHGLQ)LJXUH. If inequality aversion is zero then the 
EDE is equal to the mean health and, at a CET of $50, the standard programme would 
provide 7,395 more population HALYs than the pro-poor programme. For inequality aversion 
parameters greaWHUWKDQİ WKHSRLQWDWZKLFKWKHOLQHFURVVHVWKH[-axis, the pro-poor 
programme is preferred, implying that the decision maker is willing to sacrifice the additional 
7,395 HALYs in pursuit of lower health inequality. At this level of inequality aversion this 
would require that health gains in the poorest wealth quintile group were weighted at least 
3.86 times more highly than health gains in the richest. No research exists on the level of 
inequality aversion in Ethiopia. The appropriate level of this parameter is a matter for 
decision makers in Ethiopia, and we acknowledge both that English views are not directly 
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relevant to Ethiopia and that there is uncertainty and potential for bias in the findings for 
England. However, if there is similar inequality aversion in Ethiopia as has been estimated in 
England, the concern for inequality is large enough to choose the pro-poor vaccination 
programme at the CET of $50. 
The equity trade-off analysis at the four CET values selected for the sensitivity analyses are 
also depicted in Figure 4. At a CET of $10, the line lies above the x-axis and never crosses it 
meaning that no matter how great the inequality aversion is, the pro-poor programme would 
never be preferred because at this threshold the net health benefits are large enough that 
they are valued more highly than the gains in equity.  For CETs of $255, $619 or $1,857, the 
opposite is true. These lines lie below the x-axis and never cross it meaning that no matter 
how small the inequality aversion the pro-poor programme will always be preferred because 
at these thresholds the net health benefits are small enough in relation to the equity benefits 
that the gains in equity are valued more highly than the net health benefits. For the 
comparison between the standard- and the pro-poor- vaccine programme, a trade-off 
between equity and efficiency exists for thresholds between $27.95 and $69.45. 
 
Discussion 
In this work, we illustrated the use of DCEA in LMIC settings, using the example of 
alternative designs of the rotavirus vaccination programme in Ethiopia and focusing on the 
added value and insights that may be obtained from the methods of DCEA and ECEA in 
designing and evaluating such programmes. 
The results of the DCEA study confirmed those of the previously conducted ECEA study 
(Verguet et al., 2013a), that the standard vaccination programme introduced in Ethiopia was 
cost-effective as compared with the prior situation of no vaccination coverage, The analysis 
also confirmed that the vaccination programme delivered greater health benefits to poorer 
groups despite introducing inequality in coverage levels favouring wealthier social groups 
and urban areas.  We built on this analysis to examine an alternative design to the 
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vaccination programme to address the social inequality in coverage.  DCEA analysis of this 
re-designed programme found that such a programme would not be cost-effective relative to 
the standard programme but would reduce both inequality in coverage, and in health. By 
analysing the trade-off between cost-effectiveness and equity we found that the more 
equitable, pro-poor, programme would be preferred by a policy maker whose degree of 
inequality concern was greater than  =5.66. At current levels of health inequality in Ethiopia, 
this implied that additional health gains in the poorest wealth quintile group would need to be 
weighted approximately 4 times as highly as health gains in the richest for the re-designed 
programme to be preferred. Unlike ECEA, the DCEA methodology focused solely on health 
impacts and did not capture financial risk protection benefits or other non-health benefits 
related to household wellbeing. 
Our study has a number of limitations. We made simplifying assumptions around issues 
such as: cost savings from future treatment costs, morbidity benefits, herd effects and 
transmission effects. These all will result in the gains form the vaccine being underestimated. 
However age at death was not incorporated into the analysis, instead, overall healthy life 
expectancy was used to account for death averted which will result in the gains from the 
vaccine being overestimated. 
The lack of a vital registration system for adult mortality in Ethiopia meant that we had to 
instead rely on the use of child health data for modelling the health. Whilst rotavirus 
diarrhoea mainly affects children under five years old, the lack of adult data may be a more 
significant limitation for evaluations of interventions for diseases that affect older age groups. 
Additionally, to account for morbidity in the baseline health distribution, we used prevalence 
data for only three diseases, though these were chosen based on their contribution to the 
burden of disease in Ethiopia (GBD, 2010, IHME, 2015).  
Another issue requiring value judgement is the choice of health outcome metric and how far 
this may indirectly discriminate against disadvantaged groups.  There is a large ethics and 
economics literature on how the health-adjusted life year (HALY) and other outcome metrics 
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commonly used in health economic evaluation may implicitly discriminate against preventing 
mortality among relatively unhealthy population groups such as the poor, the elderly and the 
disabled (Edlin et al., 2013). This indirect discrimination occurs because relatively few years 
of healthy life are gained from averting the death of a relatively unhealthy individual.  It is 
important for producers and users of health economic evaluation to consider this ethical 
issue, and how far it may or may not be relevant to the case in hand.  Where the issue is 
considered relevant by stakeholders, analysts can address it using sensitivity analysis based 
on simple binary outcome metrics ± such as mortality or cases of disease averted ± which 
do not indirectly discriminate in this way although they provide an incomplete and potentially 
misleading picture of the overall health gains in other ways, as documented in the standard 
health economic evaluation literature (Drummond et al., 2015). 
 
The main strengths of DCEA are that it provides a summary measure of health inequality 
impact and allows explicit analysis of the trade-offs that can occur between maximising total 
health and reducing unfair inequality in health. There may be cases where such trade-offs do 
not occur, for example, LISROLFLHVIDOOLQWKH³ZLQ-ZLQ´TXDGUDQWRIWKHHTXLW\-impact plane, 
improving both total health and reducing health inequality. However, it will often be the case 
that by paying closer attention to additional delivery costs to reach the most disadvantaged 
groups and accounting for these implementation costs at the analysis stage will lead to more 
equitable policies being pursued.  
DCEA serves a valuable purpose, particularly for LMIC contexts, as it facilitates the 
consideration of fairer options so that the consequences of alternative uses of very scarce 
resources can be explicitly quantified in terms of both equity and cost-effectiveness. Through 
the analysis of trade-offs, DCEA can help with the assessment of policy alternatives so that 
informed decisions can be made when considering policy implementation. Additionally, use 
RIHTXLW\SDUDPHWHUVFDQKHOSZLWKWKHGHYHORSPHQWRIHTXLW\µEHQFKPDUNV¶IRUSROLF\PDNHUV
to compare across different decisions and policy choices. This can be particularly useful as a 
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way to understand the impact of policy decisions and facilitates transparency and 
consistency of decision making. 
A number of future research directions would be of value in this area. More research on the 
distribution of opportunity costs and also on levels of health inequality aversion would be of 
value. This is true for both high-income countries and LMICs. While there has been research 
in this area conducted for England (Robson et al., 2016), research of this kind repeated in 
other settings would inform further research and analyses using DCEA in other global 
contexts,. Finally, as has been noted elsewhere (Grimm et al., 2010), data availability is 
often a fundamental limitation to such analyses both in terms of vital statistics collection but 
also in terms of variation in vital statistics and delivery costs by equity-relevant parameters. 
 
Conclusion 
Policy makers in LMICs face difficult choices about which services to cover and how to scale 
up on the path to universal health coverage. This paper has outlined how DCEA can be used 
to extend current methods of economic evaluation of healthcare in LMICs so that trade-offs 
between improving total health and reducing health inequalities can be quantified and 
analysed in order to inform the decision making process.  
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Appendices 
Appendix 1 
Computation of distribution of health for Ethiopia 
This section describes the methods used to compute the distribution of healthy life 
expectancy in Ethiopia. In the absence of reliable data that can provide population estimates 
of mortality by social strata, we draw on WHO data on healthy life expectancy (HALE) and 
Ethiopia Demographic and Health Survey (EDHS) data on morbidity and mortality by 
household asset group. The computation involves three stages which are explained below 
and in Appendix Table 1. 
Stage 1: Healthy Life Expectancy 
Healthy life expectancy (HALE) is a summary measure of population health and is measured 
LQKHDOWK\OLIH\HDUV+$/<V,WLVGHYHORSHGXVLQJ6XOOLYDQ¶VPHWKRGDSSOLHGWRFRXQWU\OLIH
tables and age-sex-specific estimates of severity-adjusted equivalent years of healthy life 
lost as a fraction of total years lived by each age-sex group.  The latter is calculated by 
summing years of healthy life lost due to disability (YLD) across a comprehensive set of 
disease and injury causes drawing on analyses from the Global Burden of Disease study 
(WHO, 2014). HALE is now included in WHO life expectancy datasets and they define HALE 
DVWKH³DYHUDJHQXPEHURI\HDUVWKDWDSHUVRQFDQH[SHFWWROLYHLQ³IXOOKHDOWK´E\WDNLQJLQWR
DFFRXQW\HDUVOLYHGLQOHVVWKDQIXOOKHDOWKGXHWRGLVHDVHDQGRULQMXU\´(WHO, 2016). HALE 
was chosen as the starting point for the analysis as it uses more detailed data on morbidity 
than rival approaches such as disability-free life expectancy, which only use binary morbidity 
data on whether or not a person has disability.  By contrast, HALE uses cardinal data on 
health-related quality of life based on disease prevalence and public views about health loss 
associated with different disease states (Salomon et al., 2012). Through the inclusion in 
WHO datasets, HALE is also available for a wide range of countries, which is of particular 
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importance when data limitations are so prominent. HALE values give average measures of 
population health that take account of both quality and length of life, and therefore provide a 
reasonable starting point.  
Stage 2: Adjust HALE according to distribution of mortality 
The second stage involves weighting the average HALE values to reflect the distribution of 
mortality among the population. We use wealth quintile groups to reflect the different groups 
in the population. As no life expectancy data that is disaggregated by social characteristics is 
available, modelled life expectancies by wealth quintile (taken from Tranvag et al., 2013) 
were used to calculate relative weights which were applied to the average HALE values for 
males (54 HALYs) and females (56 HALYs) (WHO, 2015). The modelled life expectancy 
values were calculated using a modified logit life table system which requires stratified 
under-5 and adult mortality data. Under-five mortality data by gender, urban-rural residence 
and wealth quintiles from the 2011 EDHS was used. In 2011 the EDHS surveyed 17,817 
households 31% in urban areas and 69% in rural areas, interviewing 16,515 women and 
14,110 men. Adult mortality rates by the same groups were not available and were, 
therefore, calculated using adult mortality and life expectancy from the Global Burden of 
Disease study 2010 and weighted ratios of under-5 mortality rates for the respective groups 
(see Tranvag et al., 2013 for full explanation). The relative weights were calculated by 
assuming the modelled life expectancy of the middle wealth quintile, Q3, was equal to the 
mean life expectancy, and relative weights for the other quintile groups were calculated 
accordingly. By assuming that the distribution of life expectancy applies equally to the 
morbidity and mortality components of the HALE, these weights were applied as relative 
adjustment factors to the average HALE values to produce a distribution of HALE that 
reflects the distribution of life expectancy among the population according to their wealth.  
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Stage 3: Adjust HALE according to distribution of morbidity 
The third stage involves weighting the HALE values obtained in Stage 2 to reflect the 
distribution of mortality among the population using the same wealth quintile groups. This 
adjustment was based on data on the prevalence of disease disaggregated by wealth 
quintile group taken from the Ethiopia Demographic and Health Survey (Central Statistical 
Agency and ICF International, 2012). Of the available diseases for which prevalence data 
was available, those selected to form the basis of the adjustment were anaemia, diarrhoea 
and acute respiratory infection (ARI) in children. This selection was based on the diseases 
that accounted for the largest burden of disease according to the Global Burden of Disease 
study and was restricted to three diseases because of the limited number of diseases and 
health issues for which data is available (GBD, 2010, IHME, 2015). Only the prevalence in 
children was used because of the limited data on adult morbidity that was available. 
Consequently, for the morbidity adjustment it was assumed that there is equal morbidity in 
adults as in children. The average morbidity prevalence was calculated from the 3 diseases 
selected and was then subtracted from 100 to equate to the prevalence of good health. This 
was then used to calculate the relative adjustment factors for quality of life in the same way 
as for the adjustment for the distribution of life expectancy ± assuming that the prevalence of 
good health for Q3 was equal to the average. By applying these relative adjustment factors 
to the HALE values obtained in Stage 2, a HALE distribution reflecting both the distribution of 
morbidity and the distribution of life expectancy was obtained. As before, this assumed that 
the morbidity adjustment applies equally to the morbidity and mortality components of HALE. 
The baseline health distribution 
Following the adjustments for quality and length of life outlined above, the groups were 
ordered from least to most healthy and adjusted for the size of the group to produce a 
population distribution of HALE at birth (see Figure 1 of main text).  
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Assumptions 
Like many methods used in practice in the global health field, our approach involves making 
a number of assumptions in order to extract useful information from imperfect data. The 
assumptions made for this computation are as follows: 
1. The distribution of life expectancy applies equally to the morbidity and mortality 
components of the HALE. 
2. The distribution of morbidity applies equally to the mortality and morbidity 
components of the HALE. 
3. For the relative weighting used, it was assumed that wealth quintile 3 was equal to 
the average. 
4. The use of some child mortality data when modelling the distribution of life 
expectancy assumes that if child mortality is weighted properly, it is a valid proxy for 
adult mortality 
5. The use of child prevalence data to create morbidity weights assumes that there is 
equal morbidity in adults. 
As more reliable data becomes available the assumptions used to compute distributions of 
health in the future will become much less limiting. 
 
 
 
 
 
 
 
 
 
 
 
25 
 
Appendix 2 
Calculation of costs and health effects of the vaccine programme 
Costs and health effects of the vaccination programme were estimated using the same 
models as Verguet et al. (2013a). Rotavirus deaths averted ( ) were modelled as 
follows: 
 
Where,  is rotavirus vaccine effectiveness,  is coverage achieved by the vaccine 
programme,  is the relative risk of under-five mortality in wealth quintile  and  is 
the total number of under-five deaths due to rotavirus before the programme (Verguet et al., 
2013b). 
Costs incurred per capita ( ), from a government perspective, of implementing the 
programme were also calculated as: 
 
Where,  is the cost per dose of the vaccine and  is the cost per dose of 
the programme (Verguet et al., 2013b). 
 
All parameters used within the above model calculations are reported in Table 1 of the main 
paper. 
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Appendix 3 
Distribution of opportunity cost 
In the primary analysis the opportunity costs ± i.e. the health that is given up elsewhere in 
the system as a consequence of the additional costs incurred by introducing the vaccine 
programme ± DUHDVVXPHGWRWDNHDQLQYHUWHGµ8¶VKDSHGGLVWULEXWLon. This is based on the 
assumption that the poorest group will have the lowest opportunity costs, as coverage often 
does not reach them, while the richest group will have similarly low opportunity costs as they 
are most likely to take advantage of private healthcare.  An assumption around the 
distribution of opportunity costs was necessary given the lack of data. However, alternative 
assumptions around the distribution of opportunity costs were also explored. They are 
presented here, along with the effect the different assumptions have on the results.  
The alternative assumptions around the distribution of opportunity costs that were explored 
are as follows: 
1. Opportunity costs borne proportionately more by high income groups 
2. Opportunity costs borne proportionately more by low income groups 
3. Opportunity costs equally distributed across all wealth quintile groups  
For each case, the proportion of opportunity cost borne by each wealth quintile group is 
presented in Appendix Table 2. The resulting distributions of net health effect in each case 
are presented in Appendix Figures 1-3. This shows how the assumption taken on the 
distribution of opportunity costs can impact the results and the conclusions drawn 
highlighting the importance of careful consideration of the distribution of opportunity costs 
within an analysis and also the need for further research in this area.   
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Table 1: Base case parameters used to model each scenario 
Parameters that are the same across vaccination programmes Source 
Population (annual cohort of live 
births) 
2,800,000 Based on (Central 
Statistical Agency 
[Ethiopia], 2014)  Urban  467,622 
 Rural 2,332,378 
Rotavirus death rate per 1000 
live births 
5.4 Based on (Liu et al., 
2012, Tate et al., 2012) 
Relative risk ratio of rotavirus 
mortality 
 Based on  (Rheingans et 
al., 2012) 
 Ratio of poorest to richest 
quintile group 
2.9 
 Risk index, poorest to richest 
quintile group 
1.34, 1.23, 1.06, 0.91, 0.46 
Vaccine effectiveness (%) (per 2-
dose course) 
49 (Madhi et al., 2010) 
Vaccine price (per 2-dose course) $5.00 (Global Alliance for 
Vaccines and 
Immunization) 
Vaccine price with GAVI subsidy 
(per 2-dose course) 
$0.40 
Cost-effectiveness threshold 
(base case) 
$50 Based on (Woods et al., 
2016) 
Cost-effectiveness threshold 
range (sensitivity analyses) 
$10-$1,857 Based on (Woods et al., 
2016, Evans et al., 
2005) 
Distribution of opportunity cost 
(proportion of cost borne by the 
poorest to richest quintile group) 
0.185, 0.21, 0.21, 0.21, 0.185 Assumed 
Parameters that differ across vaccination programmes 
 
No 
Vaccination 
Standard 
Vaccination1 
Pro-poor 
Vaccination2 
Source 
Incremental vaccination delivery 
cost (per 2-dose course) 
   Based on (Atherly et al., 
2012, Wolfson, 2008, Le 
Gargasson et al., 2015, 
Schütte et al., 2015) 
 Urban $0 $0.50 $0.50 
 Rural $0 $0.50 $1.00 
Vaccination coverage (%) 
(average proportion receiving 
the 2-dose course) 
0 56 62 1(Central Statistical 
Agency (CSA) [Ethiopia] 
and ICF, 2016); 
2Hypothetical 
Within group vaccination 
coverage (%) (poorest to richest 
quintile group) 
0 46, 49, 52, 
63, 78 
56, 56, 56, 
63, 78 
1(Central Statistical 
Agency (CSA) [Ethiopia] 
and ICF, 2016); 
2Hypothetical 
Parameter uncertainty ranges are not included as this is an illustrative example.  
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Table 2: Equity Impact Analysis 
Wealth 
Quintile 
Group 
Population 
births1 
Population 
after 
rotavirus 
deaths (no 
vaccination) 
Cost to vaccinate group2 (US$)  Deaths Averted 
Standard  Pro-poor Difference4 Standard Pro-poor Difference4 
Q1 
(poorest) 
677,419 673,367 1,881,870 2,191,311 309,441 919 1112 193 
Q2 643,548 639,829 1,899,755 2,210,809 311,054 897 1021 124 
Q3 598,387 595,182 1,863,377 2,159,122 295,745 815 880 65 
Q4 564,516 561,764 2,137,258 2,451,673 314,415 851 851 0 
Q5 
(richest) 
316,129 314,738 1,481,381 1,570,513 89,132 532 532 0 
Total 2,800,000 2,784,880 9,263,642 10,583,428 1,319,786 4,014 4,395 381 
         
Wealth 
Quintile 
Group 
Population HALYs Gained Health opportunity costs 
(HALYs)3 
Net health effect (HALYs) 
Standard Pro-poor Difference4 Standard Pro-poor Difference4 Standard Pro-poor Difference4 
Q1 
(poorest) 
43,642 52,786 9,144 34,275 39,159 4,884 9,367 13,627 4,260 
Q2 45,647 51,956 6,309 38,907 44,450 5,543 6,740 7,506 766 
Q3 44,920 48,469 3,549 38,907 44,450 5,543 6,013 4,019 -1,994 
Q4 46,115 46,115 0 38,907 44,450 5,543 7,207 1,664 -5,543 
Q5 
(richest) 
32,065 32,065 0 34,275 39,159 4,884 -2,211 -7,094 -4,883 
Total 212,389 231,390 19,001 185,273 211,669 26,396 27,116 19,722 -7,394 
1Based on fertility rate by quintile (DHS Ethiopia 2011) 
2Based on within group coverage, proportion in urban/rural areas and associated cost 
3Total opportunity cost is calculated as the total cost (from column 3 of the top half of the table) and a cost per HALY 
of $50 (Woods et al., 2016). Opportunity costs for each group are calculated as the total opportunity cost multiplied 
ďǇƚŚĞĨƌĂĐƚŝŽŶŽĨŽƉƉŽƌƚƵŶŝƚǇĐŽƐƚƚŚĂƚĨĂůůƐƚŽĞĂĐŚƋƵŝŶƚŝůĞ ?ĂƐƐƵŵŝŶŐĂŶŝŶǀĞƌƚĞĚ ?h ?ƐŚĂƉĞĚĚŝƐƚƌŝďƵƚŝŽŶŽĨ
opportunity cost (the distribution of opportunity cost is reported in Table 1) 
4Difference=pro-poor-standard 
Note: The rich gain the least even with lower opportunity cost because they are the least at risk. 
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Figure 1: Population distribution of health in Ethiopia: HALE at birth compared to Life 
expectancy (life expectancy from Tranvag et al., 2013)
30 
 
 
Figure 2: Net health effect of each programme compared to no vaccination (Ȝ=$50)
31 
 
 
Figure 3: Incremental analysis of pro-poor vaccine compared to standard vaccine: Cost-
effectiveness plane vs. Health equity impact plane 
Note: Panel A plots the gross health effect; Panel B plots the net health effect (taking 
account of opportunity cost). The Atkinson index of inequality is normally scaled from 0 to 1, 
where 1 represents full inequality, but we have reversed the scale so that a positive impact 
represents improved equity.
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Figure 4: Equity trade-off analysis 
Notes: 1) The health inequality aversion (x-axis) represents the strength of concern for 
reducing health rather than improving total health. 2) At the point the line crosses the x axis: 
to the left it is better to implement the standard programme, to the right it is better to 
implement the pro-poor programme.
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Appendix Table 1: Modelling the baseline health distribution 
Stage 1 Stage 2 Stage 3 
*Average HALE Wealth 
Quintile  
*Modelled 
Life 
expectancy 
Adjustment 
Factor (LE) 
Adjusted HALE 100- Average 
Morbidity 
Prevalence 
Adjustment 
Factor (QoL) 
Adjusted HALE 
Female Male Female Male Female Male 
  Q1 53.4 0.88 49.35 47.58 76.5 0.97 48.19 46.47 
  Q2 56.2 0.93 51.93 50.08 78 0.99 51.71 49.87 
56 54 Q3 60.6 1 56 54 78.33 1 56 54 
  Q4 59.9 0.99 55.35 53.38 77.97 0.99 55.09 53.13 
  Q5 62.5 1.03 57.76 55.69 82.97 1.06 61.17 58.99 
*Source: WHO, 2015 
**Source: Tranvag, Ali & Norheim, 2013 
34 
 
Appendix Table 2: Proportion of opportunity cost assigned to each wealth 
quintile group 
Wealth Quintile 
Group 
Vaccination 
Base case More high income More low 
income 
Equal 
Q1 0.185 0.1 0.3 0.2 
Q2 0.21 0.15 0.25 0.2 
Q3 0.21 0.2 0.2 0.2 
Q4 0.21 0.25 0.15 0.2 
Q5 0.185 0.3 0.1 0.2 
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